Mark E. Molitch
Northwestern University
Internal medicineUrologyEndocrinologySurgeryRenal functionIntensive care medicinePediatricsBromocriptineType 2 diabetesAcromegalyKidney diseaseProlactinomaProlactinInsulinCabergolineOctreotideType 1 diabetesDiabetes mellitusHormoneMedicineGastroenterology
439Publications
92H-index
23kCitations
Publications 431
Newest
#1Maria Fleseriu (OHSU: Oregon Health & Science University)H-Index: 33
#2Richard J. Auchus (UM: University of Michigan)H-Index: 41
Last. John D. Carmichael (SC: University of Southern California)H-Index: 20
view all 53 authors...
Summary null null Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pituitary Society convened a consensus workshop comprising more than 50 academic researchers and clinical experts to discuss the application of recent evidence to clinical practice. In advance of the virtual meeting, data from 2015 to present about screening and diagnosis; surgery, medical, and radiation therapy; and disease-related and treatmen...
Source
#1Allison J. Hahr (NU: Northwestern University)H-Index: 9
#2Mark E. Molitch (NU: Northwestern University)H-Index: 92
The most common cause of kidney failure in the United States and across the world is diabetes mellitus (DM). Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in persons with diabetes, and chronic kidney disease (CKD) further increases overall CVD risk. It is important to individualize glycemic targets for patients to maintain glucose levels that will reduce the development and progression of complications while avoiding hypoglycemia. CKD alters the relationship of glu...
Source
#2Lisa B. Nachtigall (Chestnut Hill College)H-Index: 22
Source
#2Lisa B. Nachtigall (Chestnut Hill College)H-Index: 22
PURPOSE Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly. METHODS CH-ACM-01 was an open-label trial (N = 155) and CHIASMA OPTIMAL was a double-blind placebo-controlled (DPC) trial (N = 56), both investigating OOC as maintenance therapy for patients with acromegaly who were biochemical responders receiving iSRLs. RESULTS Baseline characteristics in both trials ...
Source
Source
Source
Source
#2Mary L. JohnsonH-Index: 6
Last. Brian L. Levy (Johnson & Johnson)H-Index: 12
view all 16 authors...
OBJECTIVE CeQur Simplicity™ (CeQur, Marlborough, MA) is a 3-day insulin delivery patch designed to meet mealtime insulin requirements. A recently reported 48-week, randomized, multicenter, interventional trial compared efficacy, safety and self-reported outcomes in 278 adults with type 2 diabetes (T2D) on basal insulin therapy who initiated and managed mealtime insulin therapy with a patch pump versus insulin pen. We assessed changes in key glycemic metrics among a subset of patients who wore a ...
Source
#1Nienke BiermaszH-Index: 13
#2Maria FleseriuH-Index: 4
Last. Gerald RaverotH-Index: 6
view all 19 authors...
Source
#1Maria FleseriuH-Index: 4
#2Alexander DrevalH-Index: 4
Last. Elena GrinevaH-Index: 1
view all 19 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.